TY  - JOUR
AU  - Ducic, Tanja
AU  - Ninković, Milena
AU  - Martinez-Rovira, Immaculada
AU  - Sperling, Swetlana
AU  - Rohde, Veit
AU  - Dimitrijević, Dragoljub
AU  - Jover, Manas, Gabriel Vicent
AU  - Vaccari, Lisa
AU  - Birarda, Giovanni
AU  - Yousef, Ibraheem
PY  - 2022
UR  - http://rimsi.imsi.bg.ac.rs/handle/123456789/1540
AB  - Glioblastoma multiforme (GBM) is the most aggressive brain tumor, characterized by short median survival and an almost 100% tumor-related mortality. The standard of care treatment for newly diagnosed GBM includes surgical resection followed by concomitant radiochemotherapy. The prevention of disease progression fails due to the poor therapeutic effect caused by the great molecular heterogeneity of this tumor. Previously, we exploited synchrotron radiation-based soft X-ray tomography and hard X-ray fluorescence for elemental microimaging of the shock-frozen GBM cells. The present study focuses instead on the biochemical profiling of live GBM cells and provides new insight into tumor heterogenicity. We studied bio-macromolecular changes by exploring the live-cell synchrotron-based Fourier transform infrared (SR-FTIR) microspectroscopy in a set of three GBM cell lines, including the patient-derived glioblastoma cell line, before and after riluzole treatment, a medicament with potential anticancer properties. SR-FTIR microspectroscopy shows that GBM live cells of different origins recruit different organic compounds. The riluzole treatment of all GBM cell lines mainly affected carbohydrate metabolism and the DNA structure. Lipid structures and protein secondary conformation are affected as well by the riluzole treatment: cellular proteins assumed cross beta-sheet conformation while parallel beta-sheet conformation was less represented for all GBM cells. Moreover, we hope that a new live-cell approach for GBM simultaneous treatment and examination can be devised to target cancer cells more specifically, i.e., future therapies can develop more specific treatments according to the specific bio-macromolecular signature of each tumor type.
PB  - Amer Chemical Soc, Washington
T2  - Analytical Chemistry
T1  - Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment
EP  - 1940
IS  - 4
SP  - 1932
VL  - 94
DO  - 10.1021/acs.analchem.1c02076
ER  - 

@article{
author = "Ducic, Tanja and Ninković, Milena and Martinez-Rovira, Immaculada and Sperling, Swetlana and Rohde, Veit and Dimitrijević, Dragoljub and Jover, Manas, Gabriel Vicent and Vaccari, Lisa and Birarda, Giovanni and Yousef, Ibraheem",
year = "2022",
abstract = "Glioblastoma multiforme (GBM) is the most aggressive brain tumor, characterized by short median survival and an almost 100% tumor-related mortality. The standard of care treatment for newly diagnosed GBM includes surgical resection followed by concomitant radiochemotherapy. The prevention of disease progression fails due to the poor therapeutic effect caused by the great molecular heterogeneity of this tumor. Previously, we exploited synchrotron radiation-based soft X-ray tomography and hard X-ray fluorescence for elemental microimaging of the shock-frozen GBM cells. The present study focuses instead on the biochemical profiling of live GBM cells and provides new insight into tumor heterogenicity. We studied bio-macromolecular changes by exploring the live-cell synchrotron-based Fourier transform infrared (SR-FTIR) microspectroscopy in a set of three GBM cell lines, including the patient-derived glioblastoma cell line, before and after riluzole treatment, a medicament with potential anticancer properties. SR-FTIR microspectroscopy shows that GBM live cells of different origins recruit different organic compounds. The riluzole treatment of all GBM cell lines mainly affected carbohydrate metabolism and the DNA structure. Lipid structures and protein secondary conformation are affected as well by the riluzole treatment: cellular proteins assumed cross beta-sheet conformation while parallel beta-sheet conformation was less represented for all GBM cells. Moreover, we hope that a new live-cell approach for GBM simultaneous treatment and examination can be devised to target cancer cells more specifically, i.e., future therapies can develop more specific treatments according to the specific bio-macromolecular signature of each tumor type.",
publisher = "Amer Chemical Soc, Washington",
journal = "Analytical Chemistry",
title = "Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment",
pages = "1940-1932",
number = "4",
volume = "94",
doi = "10.1021/acs.analchem.1c02076"
}

Ducic, T., Ninković, M., Martinez-Rovira, I., Sperling, S., Rohde, V., Dimitrijević, D., Jover, M. G. V., Vaccari, L., Birarda, G.,& Yousef, I.. (2022). Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment. in Analytical Chemistry
Amer Chemical Soc, Washington., 94(4), 1932-1940.
https://doi.org/10.1021/acs.analchem.1c02076

Ducic T, Ninković M, Martinez-Rovira I, Sperling S, Rohde V, Dimitrijević D, Jover MGV, Vaccari L, Birarda G, Yousef I. Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment. in Analytical Chemistry. 2022;94(4):1932-1940.
doi:10.1021/acs.analchem.1c02076 .

Ducic, Tanja, Ninković, Milena, Martinez-Rovira, Immaculada, Sperling, Swetlana, Rohde, Veit, Dimitrijević, Dragoljub, Jover, Manas, Gabriel Vicent, Vaccari, Lisa, Birarda, Giovanni, Yousef, Ibraheem, "Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment" in Analytical Chemistry, 94, no. 4 (2022):1932-1940,
https://doi.org/10.1021/acs.analchem.1c02076 . .